MOR209/ES414, a novel bispecific antibody targeting PSMA for the treatment of metastatic castration-resistant prostate cancer

Molecular Cancer Therapeutics

Volumn 15, Issue 9, 2016, Pages 2155-2165

  Hernandez Hoyos, Gabriela ^a   Sewell, Toddy ^a   Bader, Robert ^a   Bannink, Jeannette ^a   Chenault, Ruth A ^a   Daugherty, Mollie ^a   Dasovich, Maria ^a   Fang, Hang ^a   Gottschalk, Rebecca ^a   Kumer, John ^a   Miller, Robert E ^a   Ravikumar, Padma ^a   Wiens, Jennifer ^a,b   Algate, Paul A ^a,c   Bienvenue, David ^a   McMahan, Catherine J ^a   Natarajan, Sateesh K ^a,d   Gross, Jane A ^a   Blankenship, John W ^a  

^a Emergent Product Development   (United States)

^b Eurofins Medinet Inc   (Germany)

^c Theraclone Sciences   (United States)

^d DR REDDY'S LABORATORIES LTD   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; MOR 209ES 414; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG; CD3 ANTIGEN; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; AREA UNDER THE CURVE; ARTICLE; CANCER CELL; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; COMPARATIVE STUDY; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; ELIMINATION HALF-LIFE; HUMAN; HUMAN CELL; MALE; MAXIMUM PLASMA CONCENTRATION; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MOUSE; NONHUMAN; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; PROSTATE CANCER; SHORT TANDEM REPEAT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TARGET CELL; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR CELL DESTRUCTION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; VOLUME OF DISTRIBUTION; VOLUME OF DISTRIBUTION AT STEADY-STATE; ANIMAL; ANTAGONISTS AND INHIBITORS; CYTOTOXICITY; DISEASE MODEL; DRUG DESIGN; DRUG SCREENING; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN ENGINEERING; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; DRUG DESIGN; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, TRANSGENIC; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN ENGINEERING; SINGLE-CHAIN ANTIBODIES; T-LYMPHOCYTE SUBSETS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84990966365     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0242     Document Type: Article

References (27)

1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 2004;351:1502-12.
2. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. New Engl J Med 2011;364:1995-2005.
3. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. New Engl J Med 2012;367:1187-97.
4. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54.
5. Garcia JA, Rini BI. Castration-resistant prostate cancer: many treatments, many options, many challenges ahead. Cancer 2012;118:2583-93.
6. Quinn DI, Shore ND, Egawa S, Gerritsen WR, Fizazi K. Immunotherapy for castration-resistant prostate cancer: progress and new paradigms. Urol Oncol 2015;33:245-60.
7. Chang SS. Overview of prostate-specific membrane antigen. Rev Urol 2004;6Suppl 10:S13-8.
8. O'Keefe DS, Bacich DJ, Heston WDW. Prostate specificmembrane antigen. In: Chung LWK, Isaacs WB, Simons JW, editors. Prostate cancer: biology, genetics and the new therapeutics. Totowa, NJ: Humana Press; 2001. p.307-26.
9. Wolf P. Prostate specific membrane antigen as biomarker and therapeutic target for prostate cancer. In: Spiess PE, editor. Prostate cancer - diagnostic and therapeutic advances. Munich, Germany: InTech; 2011. p.81-100.
10. Hinkle GH, Burgers JK, Neal CE, Texter JH, Kahn D, Williams RD, et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer 1998;83:739-47.
11. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004;22:2522-31.
12. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005;23:4591-601.
13. Vallabhajosula S, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA, et al. Pharmacokinetics and biodistribution of 111In- and 177Lulabeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? J Nucl Med 2005;46:634-41.
14. Galsky MD, Eisenberger M, Moore-Cooper S, Kelly WK, Slovin SF, DeLa-Cruz A, et al. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol 2008;26:2147-54.
15. Buhler P, Wolf P, Gierschner D, Schaber I, Katzenwadel A, Schultze-Seemann W, et al. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells. Cancer Immunol Immunother 2008;57:43-52.
16. Friedrich M, Raum T, Lutterbuese R, Voelkel M, Deegen P, Rau D, et al. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-bispecific BiTE antibody cross-reactive with non-human primate antigens. Mol Cancer Ther 2012;11:2664-73.
17. Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA. BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today 2005;10:1237-44.
18. World Health Organization. Proposed International Nonproprietary Names: List 111. WHO Drug Information 2014;28:251-2.
19. Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 2005;115:98-104.
20. Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM, et al. A recombinant bispecificsingle-chain antibody, CD19 xCD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000;95:2098-103.
21. McHugh S, Deighton J, Rifkin I, Ewan P. Kinetics and functional implications of Th1 and Th2 cytokine production following activation of peripheral blood mononuclear cells in primary culture. Eur J Immunol 1996;26:1260-5.
22. Kum WW, Cameron SB, Hung RW, Kalyan S, Chow AW. Temporal sequence and kinetics of proinflammatory and anti-inflammatory cytokine secretion induced by toxic shock syndrome toxin 1 in human peripheral blood mononuclear cells. Infect Immun 2001;69:7544-9.
23. Corse E, Gottschalk RA, Allison JP. Strength of TCR-peptide/MHC interactions and in vivo T-cell responses. J Immunol 2011;186:5039-45.
24. Blincyto [package insert]. Thousand Oaks, CA: Amgen Inc.
25. Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab: a historical perspective. Pharm Thera 2012;136:334-42.
26. Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013;121:5154-7.
27. + T cells. J Immunol 2014;192:3507-17.